中国北京建国门外大街 1 号国贸写字楼 2 座 12 -15 层 100004 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于华熙生物科技股份有限公司 致：华熙生物科技股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共 和国证券法》(以下简称"《证券法》")、 《上市公司股东会规则》(以下简称"《股 东会规则》")等法律、法规及规范性文件和《华熙生物科技股份有限公司章程》 (以下简称"《公司章程》")的规定，北京市通商律师事务所(以下简称"通商" 或"本所")接受华熙生物科技股份有限公司(以下简称"公司")委托，指派本所 律师出席了公司于 2025 年 6 月 11 日召开的 2024 年年度股东大会(以下简称"本 次股东大会")，并就本次股东大会的相关事项出具本法律意见书。 本法律意见书仅供公司本次股东大会之目的使用，本所律师同意将本法律意 见书随公司本次股东大会其他信息披露资料一并 ...

| 证券代码：688363 证券简称：华熙生物 公告编号：2025-021 | | | | | | | --- | --- | --- | --- | --- | --- | | 华熙生物科技股份有限公司 | | | | | | | 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | | | | | | | 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | 重要内容提示： | | | | | | | ? 本次会议是否有被否决议案：无 | | | | | | | 一、 会议召开和出席情况 | | | | | | | （一） 股东大会召开的时间：2025 年 06 日 | | 月 11 | | | | | （二） 股东大会召开的地点：浙江省杭州市钱塘区海达北路 号康洲科创园 | | | | 399 | | | B1 座 1 层 | | | | | | | （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 | | | | | | | 其持有表决权数量的情况： | | | | | | | 普通股股东人数 | | | | 188 | ...

Core Viewpoint - The announcement details the completion of the board of directors' re-election and the appointment of senior management personnel at Huaxi Biological Technology Co., Ltd. The third board of directors has been elected for a term of three years, and key management positions have been filled. Group 1: Board of Directors Election - The third board of directors was elected during the annual general meeting on June 11, 2025, with Zhao Yan, Guo Jiajun, Li Yizheng, Wang Hui, Yu Jing, and Chen Yuxin as non-independent directors, and Yao Yang, Chen Daliang, and Xu Wenming as independent directors [1][2] - Zhao Yan was elected as the chairman of the third board of directors, with a term starting from the approval date until the end of the board's term [2] - The board established several specialized committees, including the Strategy Committee, Audit Committee, Nomination Committee, Compensation and Assessment Committee, ESG Committee, and Risk Management Committee, with independent directors holding a majority in key committees [2][3] Group 2: Senior Management Appointments - Zhao Yan was appointed as the General Manager, with Guo Jiajun, Li Yizheng, Wang Hui, and Xiang Maogong appointed as Deputy General Managers. Li Yizheng also serves as the Board Secretary, and Wang Hui as the Chief Financial Officer [4] - The appointments of senior management personnel were approved by the Nomination Committee, and their qualifications were reviewed accordingly [4] - Li Yizheng holds the qualification certificate for the Board Secretary of the Shanghai Stock Exchange's Sci-Tech Innovation Board, confirming his eligibility for the position [4] Group 3: Management Profiles - Zhao Yan, born in July 1966, holds a bachelor's degree in biology and an MBA from Fordham University. She has held various leadership roles within the company since 2000 [5] - Guo Jiajun, born in September 1975, has an MBA from Fordham University and has served in various managerial positions within the company since 2002 [6] - Li Yizheng, born in September 1984, holds a master's degree in investment studies and has extensive experience in investment banking prior to joining the company in 2021 [7] - Wang Hui, born in September 1983, is a CPA and has held various financial management roles before joining the company in September 2023 [8] - Xiang Maogong, born in February 1984, has a background in microbiology and has worked in various roles in the pharmaceutical industry [8]

证券代码：688363 证券简称：华熙生物 公告编号：2025-022 华熙生物科技股份有限公司 关于公司董事会完成换届选举 暨聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华熙生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 11 日召开 公司 2024 年年度股东大会，选举产生了公司第三届董事会成员。同日，公司召 开了第三届董事会第一次会议，选举产生了第三届董事会董事长、第三届董事会 各专门委员会委员及召集人，并聘任高级管理人员。具体情况公告如下： 一、 董事会换届选举情况 （一）第三届董事会成员 经公司 2024 年年度股东大会选举，赵燕女士、郭珈均先生、李亦争先生、 汪卉先生、于静女士、陈玉鑫先生当选为公司第三届董事会非独立董事，姚洋先 生、陈达亮先生、徐文鸣先生当选为公司第三届董事会独立董事。第三届董事会 任期为自公司股东大会审议通过之日起三年。上述董事个人简历详见公司于 2025 年 5 月 20 日在上海证券交易所披露的《华熙生物科技股份有限公司关于董 事会换届选举的公告 ...

中国北京建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于华熙生物科技股份有限公司 2024 年年度股东大会的法律意见书 致：华熙生物科技股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共 和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以下简称"《股 东会规则》")等法律、法规及规范性文件和《华熙生物科技股份有限公司章程》 (以下简称"《公司章程》")的规定，北京市通商律师事务所(以下简称"通商" 或"本所")接受华熙生物科技股份有限公司(以下简称"公司")委托，指派本所 律师出席了公司于 2025 年 6 月 11 日召开的 20 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-021 华熙生物科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 06 月 11 日 （二） 股东大会召开的地点：浙江省杭州市钱塘区海达北路 399 号康洲科创园 B1 座 1 层 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 188 | | --- | --- | | 普通股股东人数 | 188 | | 2、出席会议的股东所持有的表决权数量 | 302,670,369 | | 普通股股东所持有表决权数量 | 302,670,369 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 63.2721 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 63.2 ...

Core Insights - The overall brand communication effectiveness of Shandong listed companies showed improvement in April 2025, with an average INC index of 588.49, reflecting a 0.43% increase from March [1][3] - The company with the highest increase in ranking was Zhongchuang Logistics Co., Ltd., which rose by 156 positions, while Zhiyang Innovation Technology Co., Ltd. experienced the largest drop, falling by 132 positions [1] INC Index Overview - The INC index, or Internet Communication Influence Index, serves as a quantitative evaluation system for brand communication effectiveness in the digital age [2] - The index evaluates dimensions such as communication breadth, heat, online attention, and official website presentation [2] Industry Level Analysis - The average INC index of 588.49 indicates that most brands in the industry are maturing and gaining more attention, with both brand voice and social concern on the rise [3] - The skewness coefficient of the INC index is 0.77, indicating a moderate right-skewed distribution, where a few units exhibit outstanding communication influence, enhancing the overall industry INC level [3] Communication Breadth Analysis - The average communication breadth index for April was 2.73, categorized as "standard level" [5] - Eight companies achieved the highest level (5), including Qingdao Beer Co., Ltd. and Haier Smart Home Co., Ltd. [5] - A total of 68 companies reached level 4 ("upgraded level"), while 212 companies were at level 3 ("standard level") [5] Communication Heat Analysis - The average communication heat index was 2.36, also at the "standard level" [6] - Five companies reached the highest level (5), including Qingdao Beer Co., Ltd. and Haier Smart Home Co., Ltd. [7] - A total of 50 companies achieved level 4, indicating strong activity and high information engagement [7][8] Online Attention Analysis - The average online attention index was 1.6, categorized as "regional attention" [9] - 107 companies reached level 3 or above ("national attention"), including Qingdao Beer Co., Ltd. and Haier Smart Home Co., Ltd. [10] - 114 companies were at the lowest level ("sporadic attention"), indicating low brand awareness [10] Official Website Presentation Analysis - The average official website presentation index was 1.08, below the "standard level" [11] - Two companies achieved the highest level (5), including Haier Smart Home Co., Ltd. [12] - A total of 176 companies were at the lowest level ("deep water level"), indicating poor website visibility [12]

来源：中国新闻网 中新网兰州6月11日电 (张婧 程涛)在甘肃省临夏县的山间地头，这片位于黄土高原与青藏高原过渡带的 县域，7.5万亩啤特果树正舒展枝叶。这种形似梨、味甘涩的西北特有果实，曾是临夏县的生态底色， 亦是当地农民增收的传统依托。 但长期以来，鲜果销售的单一模式让产业陷入"靠天吃饭"的困局。如何让"绿叶子"变成"金果子"？临夏 县将目光投向千里之外的山东省济南市高新区，那里有一家全球玻尿酸行业龙头企业华熙生物科技股份 有限公司。 5月底，位 于甘肃省临夏回族自治州临夏县的一家生物科技公司生产车间内，进行啤特果原液生产。汤晓亮 摄 与济南高新区对接中，临夏县了解到上述公司的生物科技研发能力，经过前期调研，双方决定以啤特果 原液为核心开发护肤产品。作为甘鲁两省重点产业协作项目，合作成立华熙济高生物科技(甘肃)有限公 司，是甘肃省首家化妆品新原料生产企业。 华熙济高生物科技(甘肃)有限公司副总经理尹始杰说，为了实现全产业链生产的目标，投入东西部协作 资金4100万元，提升改造项目厂房及仓库改建，啤特果原液生产设备均已落位安装，目前正在有序调试 生产设备。预计2025年8月投产，当年可实现产值1000万元， ...

Core Viewpoint - The ongoing dispute between Juzi Biotech and Huaxi Biotech highlights significant issues within the domestic beauty industry, including unclear standards and a crisis of consumer trust [4][7][26]. Group 1: Company Developments - Juzi Biotech's major shareholder announced plans to increase its stake in the company by at least 200 million HKD, leading to a temporary stock price increase of 4.15% [3][18]. - Despite the initial stock price rise, Juzi Biotech's shares fell again shortly after, indicating a lack of sustained investor confidence [4][5]. - In contrast, Huaxi Biotech reported a significant decline in revenue and profit, with a revenue of 5.317 billion RMB, down 11.61% year-on-year, and a net profit drop of 70.59% to 174 million RMB [22][25]. Group 2: Market Dynamics - The competition between Huaxi Biotech and Juzi Biotech has drawn attention to the effectiveness of hyaluronic acid versus the emerging trend of recombinant collagen, with predictions indicating that the collagen market could surpass hyaluronic acid by 2026 [19][25]. - Juzi Biotech's revenue reached 5.539 billion RMB, a year-on-year increase of 57.17%, while its net profit grew by 42.4% to 2.062 billion RMB [22][25]. Group 3: Industry Issues - The dispute has revealed a lack of rigorous standards and clear definitions in the beauty industry, contributing to consumer skepticism [7][26]. - Industry insiders have pointed out that the marketing strategies often overshadow research and development, with Juzi Biotech's R&D expenditure being significantly lower than that of its competitors [27][29]. - The ongoing debate over ingredient efficacy may serve as a catalyst for improved transparency and standards within the industry, potentially benefiting consumers and companies alike [29][30].

Group 1 - The beauty and personal care sector has shown strong performance in Q1 2025, with the SW Beauty Care Index rising by 13.4%, leading all 31 SW primary industries [4][10][12] - The cosmetics segment is focusing on enhancing brand matrices and introducing new ingredients, benefiting from an optimized competitive landscape [4][6] - The medical beauty market is evolving with new products stimulating consumer interest, and domestic companies are expected to become major competitors in the light medical beauty sector [4][6] Group 2 - The e-commerce sector is witnessing new consumption models and brands, which are helping to drive growth in the industry [4][6] - The report recommends several companies in the cosmetics sector, including Up Beauty and Proya, which have low PE multiples and strong growth potential [4][6] - In the medical beauty segment, companies with high R&D barriers and strong profitability, such as Aimeike, are highlighted as key investment opportunities [4][6] Group 3 - The personal care market is projected to reach CNY 283.3 billion by 2024, with a compound annual growth rate (CAGR) of 8.4% from 2023 to 2028 [32][34] - Domestic brands are increasingly replacing foreign brands in the personal care sector, with a notable rise in innovative products and marketing strategies [32][36] - The high-end market is experiencing significant growth, with premium products seeing a 27% increase in average transaction value in H2 2024 [44]